Beth Porter
Nurse Practitioner · Olean, NYNPI 1205338613
Payments from drug & device makers
Across 360 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$465
- Pfizer$433
- Gilead$411
- Johnson & Johnson$385
- Ardelyx, Inc.$279
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,86799%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 149 | $2,218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $465 |
| Pfizer | 28 | $433 |
| Gilead | 20 | $411 |
| Johnson & Johnson(2 entities) | 24 | $385 |
| Ardelyx, Inc. | 9 | $279 |
| Phathom Pharmaceuticals, Inc. | 22 | $278 |
| Aimmune Therapeutics, Inc. | 13 | $222 |
| Bristol Myers Squibb | 10 | $182 |
| Madrigal Pharmaceuticals | 7 | $156 |
| QOL Medical, LLC | 15 | $128 |
| Lilly USA, LLC | 10 | $123 |
| Nestle Healthcare Nutrition Inc. | 5 | $104 |
| Merck | 6 | $90 |
| Boehringer Ingelheim | 4 | $84 |
| Intercept Pharmaceuticals, Inc. | 4 | $75 |
| Sandoz | 2 | $57 |
| Braintree Laboratories, Inc. | 3 | $51 |
| Amgen | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Intuitive Surgical | 1 | $32 |
| Novo Nordisk | 1 | $26 |
| Immunitybio, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
How this compares
$5,953 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $331,972 |
| Humira(Cf) PenAdalimumab | 25 | $201,417 |
| RinvoqUpadacitinib | 22 | $157,181 |
| ZenpepLipase/Protease/Amylase | 22 | $88,928 |
| LinzessLinaclotide | 83 | $50,604 |
| IbsrelaTenapanor Hcl | 14 | $24,582 |
| CreonLipase/Protease/Amylase | 12 | $23,209 |
| PentasaMesalamine | 16 | $23,015 |
| Mesalamine | 36 | $16,153 |
| TrulancePlecanatide | 11 | $10,678 |
| Colestipol Hcl | 187 | $9,786 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 50 | $8,014 |
| Pantoprazole Sodium | 485 | $4,851 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 26 | $4,407 |
| Famotidine | 310 | $3,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $385 | $331,97213 claims |
| AbbVieRinvoq, Linzess, Creon | $2,218 | $230,994117 claims |
| Aimmune Therapeutics, Inc.Zenpep | $222 | $88,92822 claims |
| Ardelyx, Inc.Ibsrela | $279 | $24,58214 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $33 | $10,67811 claims |
| Braintree Laboratories, Inc.Sutab | $51 | $8,01450 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $20 | $4,40726 claims |
| SandozLansoprazole | $57 | $2,10728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Olean
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.